Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
L Baglietto, R Torrisi, G Arena, F Tosetti, AG Gonzaga, W Pasquetti, C Robertson, A Decensi
Cancer Detect Prev | Published : 2000
Fenretinide is a vitamin A derivative under investigation in cancer prevention trials. Because all available pharmacologic and toxicologic data were obtained from breast cancer patients, we measured plasma drug, metabolite, and vitamin A levels and studied their relationship with visual and ocular symptoms in a cohort formed mostly by male subjects belonging to a bladder cancer prevention trial. After 1 year, the mean plasma retinol levels (+/- standard deviation [SD]) were 168.2 +/- 75.8 ng/ml in 31 subjects treated with fenretinide and 594.5 +/- 168.4 ng/ml in 36 control subjects (P < .001). Plasma retinol levels were correlated inversely to drug and metabolite concentrations, which in tur..View full abstract
Awarded by NCI NIH HHS